文献速递泌尿男性生殖肿瘤支持与姑息治疗

镭-223二氯化物(Ra-223)对住院的影响:来自3期随机ALSYMPCA试验的分析

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
PubMed 文献 · Eur J Cancer · 2016-12-06

基于ALSYMPCA试验,分析镭-223对症状性骨转移去势抵抗性前列腺癌患者住院的影响。随机后前12个月,镭-223组至少一次住院事件比例显著低于安慰剂组(37.0% vs 45.5%,P=0.016),人均住院天数显著减少(4.44 vs 6.68天,P=0.004),但人均住院事件次数无显著差异(0.69 vs 0.79,P=0.226)。

要点

  • 镭-223组至少一次住院事件比例显著低于安慰剂组(37.0% vs 45.5%,P=0.016)。
  • 镭-223组人均住院天数显著少于安慰剂组(4.44 vs 6.68天,P=0.004)。
  • 人均住院事件次数两组无显著差异(0.69 vs 0.79,P=0.226),可能与镭-223组随访时间显著更长有关(7.82 vs 6.92个月,P<0.001)。

核心结论

  • 镭-223治疗可减少症状性骨转移去势抵抗性前列腺癌患者的住院天数,结合生存获益和至症状性骨骼事件时间的延长,可能有助于改善健康相关生活质量。

研究设计与样本

  • ALSYMPCA为3期随机试验,纳入有症状性骨转移且无已知内脏转移的去势抵抗性前列腺癌患者,前瞻性收集随机后前12个月内的医疗资源使用(包括住院事件和天数)。

主要发现

  • 镭-223组至少一次住院事件比例为37.0%(218/589),安慰剂组为45.5%(133/292),差异显著(P=0.016)。
  • 人均住院事件次数镭-223组为0.69,安慰剂组为0.79,无显著差异(P=0.226),可能与镭-223组随访时间显著更长有关(7.82个月 vs 6.92个月,P<0.001)。
  • 人均住院天数镭-223组为4.44天,安慰剂组为6.68天,差异显著(P=0.004)。
  • 首次症状性骨骼事件前人均住院天数镭-223组为2.35天,安慰剂组为3.36天;症状性骨骼事件后人均住院天数镭-223组为7.74天,安慰剂组为9.19天。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Symptomatic skeletal events (SSEs) commonly occur in patients with bone metastases, often leading to hospitalisations and decreased quality-of-life. In the ALSYMPCA trial, radium-223 significantly improved overall survival (hazard ratio 0.70, 95% confidence interval [CI] 0.58-0.83, P < 0.001) and prolonged time to first SSE (hazard ratio 0.66, 95% CI 0.52-0.83, P = 0.00037) and subsequent SSE (hazard ratio 0.65, 95% CI 0.51-0.83, P = 0.00039) versus placebo in patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases. Health care resource use (HCRU), including hospitalisation events and days, were prospectively collected in ALSYMPCA. We assessed health care resource use for the first 12 months post-randomisation. Significantly fewer radium-223 (218/589; 37.0%) versus placebo patients (133/292; 45.5%) had at least one hospitalisation event (P = 0.016). However, mean number of hospitalisation events per patient was similar (radium-223 0.69 versus placebo 0.79, P = 0.226), likely due to the significantly longer follow-up time for radium-223 (7.82 months versus 6.92 months for placebo; P < 0.001). There were significantly fewer hospitalisation days per patient for radium-223 (4.44 versus 6.68, respectively, P = 0.004). The reduction in hospitalisation days with radium-223 was observed both before first SSE (2.35 days versus 3.36 days, respectively) and after SSE (7.74 days versus 9.19 days, respectively). Our data suggest that this reduced hospital days along with the survival benefit and reduction in time to SSEs with radium-223 treatment may contribute to improvements in health-related quality-of-life in patients with castration-resistant prostate cancer with symptomatic bone metastases (ALSYMPCA ClinicalTrials.gov number, NCT00699751.).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Parker C, Zhan L, Cislo P, et al. Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. Eur J Cancer. 2016. PMID: 27930924. doi:10.1016/j.ejca.2016.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。